Cargando…
Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin
The efficacy of cisplatin-based chemotherapy in ovarian cancer is often limited by the development of drug resistance. In most ovarian cancer cells, cisplatin activates extracellular signal-regulated kinase1/2 (ERK1/2) signalling. Phosphoprotein enriched in astrocytes (PEA-15) is a ubiquitously expr...
Autores principales: | Dilruba, Shahana, Grondana, Alessia, Schiedel, Anke C., Ueno, Naoto T., Bartholomeusz, Chandra, Cinatl Jr, Jindrich, McLaughlin, Katie-May, Wass, Mark N., Michaelis, Martin, Kalayda, Ganna V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072772/ https://www.ncbi.nlm.nih.gov/pubmed/32102425 http://dx.doi.org/10.3390/cells9020515 |
Ejemplares similares
-
Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach
por: Sarin, Navin, et al.
Publicado: (2018) -
Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G(2)/M cell cycle arrest
por: Sarin, Navin, et al.
Publicado: (2017) -
Drug-adapted cancer cell lines as preclinical models of acquired resistance
por: Michaelis, Martin, et al.
Publicado: (2019) -
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017) -
COVID-19-Related Coagulopathy—Is Transferrin a Missing Link?
por: McLaughlin, Katie-May, et al.
Publicado: (2020)